The global infectious diseases market size reached USD 21.74 billion in 2024, grew to USD 23 billion in 2025, and is projected to hit around USD 38.19 billion by 2034, expanding at a CAGR of 5.8% during the forecast period from 2025 to 2034.
By considering the global health disparities, world leaders are contributing to advanced immunization efforts. For instance, in June 2025, Gavi, the Vaccine Alliance, secured more than US$9 billion in support from world leaders at the Global Summit: Health and Prosperity through Immunization held in Brussels over the next 5 years of its strategic period from 2026-2030.
There are numerous developments in vaccines for human trials to ensure the safety and efficacy of vaccines. For instance, in July 2025, the Coalition for Epidemic Preparedness Innovations (CEPI) announced it was providing US$17.3 million to Public Health Vaccines to advance its Nipah vaccine through early-stage clinical testing.
The R&D process for infectious diseases involves discovery, preclinical research, clinical development, regulatory review, approval, manufacturing, and post-marketing surveillance.
Key Players: Roche, GlaxoSmithKline, Johnson & Johnson, Sanofi, Pfizer.
Clinical trial phases for infectious diseases include phase I, phase II, phase III, and phase IV trials that focus on the safety, efficacy, and post-marketing surveillance. Moreover, the major regulatory agencies across the U.S., India, the WHO, and Europe contribute to the regulatory approvals.
Key Players: Moderna and BioNTech, Merck & Co., Bavarian Nordic, Vir Biotechnology, and Sanofi.
The various interventions, disease-specific education, patient and family resources, advocacy, and counselling are integral parts of patient support and services for people.
Key Players: Novartis, AstraZeneca, AbbVie, Merck, Pfizer.
In October 2024, Annaliesa Anderson, Ph.D., Senior Vice President and Head, Vaccine Research and Development, Pfizer, declared that Pfizer remains prominent for vaccine and therapeutic development in respiratory and infectious diseases. She also proclaimed that IDWeek 2024 stands as an exclusive platform to introduce Pfizer’s innovative advancements and interact with the scientific community due to the effective work of Pfizer to tackle challenges posed by infectious diseases.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
